We propose that personalized, autologous transplantation can be developed for certain blood-related diseases, such as leukemia, using normal CD34+ cells isolated from a small volume of mPB after efficient ex vivo expansion in HEM. This evidence concerns the gene CD34 and glycogen storage disease VI.